FEDERAL COURT OF AUSTRALIA
Green v Johnson and Johnson Pacific Pty Ltd [2025] FCA 583
File number: VID 1395 of 2024 Judgment of: MOSHINSKY J Date of judgment: 2 June 2025 Catchwords: PRACTICE AND PROCEDURE – representative proceeding – pleadings – strike out application – where the respondent sold medication for cold and flu – where the applicant alleged that the packaging stated that the products provided effective relief from a blocked nose etc – where the applicant alleged that in and by the packaging, the respondent’s distribution activities and the respondent’s marketing activities, the respondent represented that the products provided effective relief from a blocked nose etc – whether the pleading alleges all material facts or is otherwise defective Legislation: Competition and Consumer Act 2010 (Cth)
Federal Court of Australia Act 1976 (Cth)
Federal Court Rules 2011, rr 16.02, 16.21
Cases cited: Banque Commerciale SA, En Liquidation v Akhil Holdings Ltd [1990] HCA 11; 169 CLR 279
Berry v CCL Secure Pty Ltd [2020] HCA 27; 271 CLR 151
Gall v Domino’s Pizza Enterprises Ltd (No 2) [2021] FCA 345; 391 ALR 675
Division: General Division Registry: Victoria National Practice Area: Commercial and Corporations Sub-area: Regulator and Consumer Protection Number of paragraphs: 47 Date of hearing: 2 June 2025 Counsel for the Applicant: Mr WAD Edwards KC with Mr S Puttick Solicitor for the Applicant: JGA Saddler Counsel for the Respondent: Mr I Ahmed SC with Mr J Burnett and Ms E Hall Solicitor for the Respondent: Herbert Smith Freehills ORDERS
VID 1395 of 2024 BETWEEN: BADEN GREEN
Applicant
AND: JOHNSON AND JOHNSON PACIFIC PTY LTD
Respondent
ORDER MADE BY:
MOSHINSKY J
DATE OF ORDER:
2 JUNE 2025
THE COURT ORDERS THAT:
1.The following paragraphs of the amended statement of claim be struck out:
(a)paragraphs 76, 81 and 86;
(b)paragraphs 77, 79, 82, 84, 87 and 89; and
(c)paragraph 97.
2.The applicant provide further and better particulars of the allegation in paragraph 100 as soon as reasonably practicable.
3.The interlocutory application filed by the respondent dated 14 April 2025, otherwise be dismissed.
4.By 4.00 pm on 30 June 2025, the applicant serve a proposed further amended statement of claim.
5.By 4.00 pm on 28 July 2025, the applicant file and serve a further amended statement of claim.
6.The applicant pay the respondent’s costs of the interlocutory application.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
MOSHINSKY J:
Introduction
By interlocutory application, the respondent (JJP) seeks strike out of several paragraphs of the applicant’s amended statement of claim dated 19 March 2025 (ASOC).
JJP’s interlocutory application is dated 14 April 2025. It is supported by an affidavit of Jason Betts, a partner of Herbert Smith Freehills, the solicitors acting for JJP in the proceeding, dated 14 April 2025. There is no affidavit material in response.
The interlocutory application seeks an order…
Keep reading for free
Create a free CaseChat account to read Green v Johnson and Johnson Pacific Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2025] FCA 583
- Decision Date
CaseChat Overview and Summary
The court examined whether the plaintiff's statement of claim contained all the material facts necessary for the defendant to adequately respond or if the allegations were otherwise defective. Specifically, the court considered the clarity and specificity of the allegations related to the packaging and marketing claims, as well as whether the plaintiff had provided sufficient particulars to substantiate the claims made. The court determined that while some parts of the pleadings were adequately detailed, others lacked the necessary specificity and clarity to proceed without further information.
In its ruling, the court found that certain paragraphs of the plaintiff's statement of claim were too vague or misleading and, therefore, struck them out. The court also required the plaintiff to provide further particulars on specific allegations to ensure that the defendant could properly respond to the claims. The court dismissed the defendant's motion to strike out other parts of the claim, allowing the plaintiff an opportunity to replead. The court set deadlines for the plaintiff to serve and file an amended statement of claim and further particulars, and ordered the plaintiff to pay the defendant's costs for the interlocutory application.
The court's final orders included striking out specific paragraphs of the plaintiff's statement of claim, requiring further particulars on certain allegations, dismissing the defendant's motion to strike out other parts of the claim, and setting deadlines for the plaintiff to amend the statement of claim and provide additional particulars. The plaintiff was also ordered to pay the defendant's costs for the interlocutory application.
Orders
Orders of the court
1. The following paragraphs of the amended statement of claim be struck out:
(a) paragraphs 76, 81 and 86;
(b) paragraphs 77, 79, 82, 84, 87 and 89; and
(c) paragraph 97.
2. The applicant provide further and better particulars of the allegation in paragraph 100 as soon as reasonably practicable.
3. The interlocutory application filed by the respondent dated 14 April 2025, otherwise be dismissed.
4. By 4.00 pm on 30 June 2025, the applicant serve a proposed further amended statement of claim.
5. By 4.00 pm on 28 July 2025, the applicant file and serve a further amended statement of claim.
6. The applicant pay the respondent’s costs of the interlocutory application.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Section F (paragraphs 113 to 124) contains allegations of loss and damage and diminution in value.Consideration I will deal with each group of paragraphs as set out in the introduction to these reasons.Paragraphs 73 to 75 These paragraphs contain pleadings in relation to JJP’s alleged packaging activities, distribution activities and marketing activities. These paragraphs are expressed generally, in the sense that they apply to all of the relevant products without distinction. These paragraphs are expressed in clear terms and do not necessarily present any difficulty if considered in isolation. The real issue is what is sought to be made of these paragraphs in later paragraphs of the pleading (namely, paragraphs 77, 79, 82, 84, 87 and 89). I consider it preferable to consider the pleading issue raised by JJP when I come to consider those paragraphs. I do not consider it necessary to strike out paragraphs 73 to 75.Paragraphs 76, 81 and 86 Paragraph 76 (without mark-up) is expressed as follows:At all material times, through the J&J Pacific Packaging Activities, the packaging of each of:(a) Benadryl Mucus Relief Plus Decongestant Oral Liquid;(b) Benadryl PE Chesty Cough & Nasal Decongestant Oral Liquid;(c) Benadryl PE Dry Cough & Nasal Congestion Oral Liquid;(d) Codral Cold & Flu;(e) Codral Cold & Flu Oral Powder;(f) Codral Cold & Flu + Dry Cough;(g) Codral Cold & Flu + Mucus Cough;(h) Codral Cold & Flu + Mucus Cough Oral Powder;(i) Codral Day & Night;(j) Codral Day & Night + Dry Cough;(k) Codral Decongestant;(l) Codral Dry Cough + Cold Oral Liquid;(m) Codral Mucus Cough + Cold Oral Liquid;(n) Codral Night;(o) Codral Plus Mucus Cough Liquid + Cold & Flu;(p) Sudafed PE Nasal Decongestant;(q) Sudafed PE Night;(r) Sudafed PE Sinus + Allergy & Pain Relief;(s) Sudafed PE Sinus + Anti Inflammatory Pain Relief;(t) Sudafed PE Sinus + Pain Relief; and(u) Sudafed PE Sinus + Pain Relief Day & Night,has stated that the respective product provides effective relief from a blocked nose (Blocked Nose Packaging).Particulars(A)Particulars are provided as Annexure “A”.(B)Further particulars will be provided following evidence and disclosure.(C)“Blocked nose” means swelling in the nasal passages and sinuses.(D)“Runny nose” means secretions in the nasal passages and sinuses.(E)“Sinus pressure” means pain and pressure in the nasal passage and sinus associated with blocked nose and runny nose.(F)“Effective relief” means the reasonable expectation that, in a significant proportion of the target population, the pharmacological effect of the drug, when used under adequate directions for use and warnings against unsafe use, will provide clinically significant relief of the type claimed. In my view, the way that the above paragraph is expressed suggests that the packaging for each of the relevant products stated that the product “provides effective relief from a blocked nose” (not merely words to that effect or words from which such a statement is to be implied). However, it seems that the packaging for at least some of the relevant products did not contain such a statement.